SynthesisBritish journal of haematology2022

Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.

Liat Shargian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.